Previous Article | Next Article ![]()
Journal of Virology, December 2008, p. 11609-11618, Vol. 82, No. 23
0022-538X/08/$08.00+0 doi:10.1128/JVI.00952-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
,
John T. West,1,
Hong Zhang,1
Danielle M. Shea,1
Tendai J. M'soka,2 and
Charles Wood1*
Nebraska Center for Virology, and The School of Biological Sciences, University of Nebraska, Lincoln, Nebraska 68583-0900,1 Department of Pediatrics, University Teaching Hospital, Lusaka 10101, Zambia2
Received 7 May 2008/ Accepted 2 September 2008
|
|
|---|
|
|
|---|
A number of factors have been suggested to affect the transmission of specific viral species. Genetic analyses of the env gene have suggested selective transmission of R5-utilizing HIV-1 during perinatal transmission from chronically infected donors (37, 40). However, other analyses have shown a stochastic pattern with transmission of multiple and/or major maternal HIV-1 variants (10, 19, 24). It has also been suggested that the virus variants more resistant to neutralization are preferentially transmitted perinatally (33). Neutralizing antibody response in the host may be associated with a replicative cost to the virus, and a compromise for the virus between immune escape and replication adaptability to the host could occur (5, 9, 28). It is likely that other biological properties of the virus may play roles to favor perinatal transmission; such properties may include enhanced viral replicative fitness of the transmitted viruses.
HIV-1 replicative fitness is related to pathogenicity, virulence, drug-resistant mutations, and disease progression (4, 13, 30, 35). The fitness of different HIV-1 subtypes was also found to correlate with their prevalence in the human population (17, 26, 31). Despite these observations, the association between HIV-1 replicative fitness and transmission is poorly defined, and information addressing an association with perinatal transmission is essentially nonexistent. Since, in the absence of drug treatment, HIV-1 replicative fitness is largely determined by the functions of Env (4, 22, 31), it is anticipated that replicative fitness might also impact virus transmission. This concept has heretofore not been tested, and therapy-naive mother-infant pairs (MIPs) in our study provide a unique opportunity to examine the properties of transmitted viruses from mother to child. As the perinatally transmitted virus should be the target of vaccine strategies, information on its biological phenotype could be directly relevant to the development of a vaccine. Such information also provides insight into mechanisms to prevent such transmission.
We have been studying a Zambian mother-infant cohort for perinatal transmission of subtype C HIV-1 and have analyzed the viral env quasispecies of several MIPs during perinatal transmission. We found that there was a reduction in the viral quasispecies during perinatal transmission from mothers who were chronically infected (41). In contrast, such a reduction was not observed in mothers who were acutely infected (14). In this study, we investigated the fitness of the viral Env, which may affect perinatal transmission, from seven MIPs infected by subtype C HIV-1. Five pairs were from a chronically infected source, and the other two pairs were from an acutely infected source. We found that recombinant viruses carrying the V1 to V5 region of Env of the infant viruses from all chronically infected MIPs have higher replicative fitness levels than the viruses infecting the mothers. In contrast, as expected, the Env from the acutely infected MIPs did not show such properties since both the mother and infant viruses had undergone recent transmission. Our results suggest that the Env protein affects viral fitness, which plays a role in perinatal transmission. Here, we show that transmitted viruses have biological properties, such as enhanced replicative fitness, that favor perinatal transmission and may provide new targets for intervention.
|
|
|---|
Cell and virus cultures. 293T and TZM-bl cells were obtained from the NIH AIDS Research and Reference Reagent Program and maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) and 100 µg/ml penicillin-streptomycin. U87-CD4-CCR5 cells (kindly provided by Lee Ratner, Washington University) were propagated in DMEM supplemented with 10% FBS, 4 mM L-glutamine, 1 mM sodium pyruvate, 200 µg/ml G418, and 1 µg/ml puromycin (27). The 50% tissue culture infective dose of each recombinant virus stock was determined by infecting TZM-bl cells (39) with fourfold serial dilutions of virus as described previously (21).
Cloning and expression of Env glycoprotein. The cloning of the V1 to V5 (V1-V5) regions of env derived from patients and the sequences of the Env clones used for this study were described previously (41). For the chronically infected MIPs (pairs 2617, 1449, 1084, 2669, and 2873), maternal samples collected at delivery and infant samples collected at the first postpartum HIV-1 PCR-positive time point were defined as baseline specimens. For acutely infected MIPs (pairs 834 and 2660), the baseline specimens were obtained at the time of seroconversion. For this study, the env V1-V5 regions were subcloned from the selected clones by amplifying the insert from the pGEM-T Env clones using the sense primer C-DraIII (5'-TGACCCCACTCTGTGTCACTTTA-3') or C-PshAI (5'-TGGGACCAAAGTCTAAAGCCATGTGT-3') and antisense primer C-AvrII (5'-CTATTCCTAGGGGCTTAATTTCTACCACTT-3') containing restriction enzyme DraIII/PshAI and AvrII sites for further subcloning. PCR was carried out at 95°C for 2 min, followed by 25 cycles at 95°C for 30 s, 55°C for 30 s, and 68°C for 1 min, followed by 1 cycle at 68°C for 7 min. The amplified products were subcloned into pSP72 NLA/S/Av (envelope gene of NL4.3 modified with AgeI/SbfI/AvrII for cloning purposes) shuttle vector and pSRHS NLA/S/Av expression vector to determine if the Env sequences were functional by fusion analysis. Env was expressed as a chimeric protein with the patient's Env V1-V5 region and HIV-1 strain NL4.3. Fusion assays were carried out as described previously (8). Between four and seven representative functional and fusion-positive Env clones from each MIP baseline were available for the growth competition analysis.
Generation of recombinant HIV-1 expressing EGFP or DsRed2 fluorescent proteins.
To generate enhanced green fluorescent protein (EGFP)-tagged or Discosoma sp. red fluorescent protein (DsRed2)-tagged recombinant HIV-1, the entire chimeric env was amplified from the pSP72 NLA/S/Av or pSRHS NLA/S/Av plasmid clones with sense primer EnvB-F (5'-AGAAAGAGCAGAAGACAGTGGCAATGA-3') and antisense primer EnvB-R (5'-TTGTACTACTTCTATAACCTTATCTGT-3'). The PCR parameters were 1 cycle at 95°C for 2 min; 30 cycles at 95°C for 30 s, 55°C for 30 s, and 68°C for 2 min and 30 s; and 1 cycle at 68°C for 10 min. The NL4.3
EnvEGFP or NL4.3
EnvDsRed2 vectors (kindly provided by Miguel E. Quinones-Mateu, Case Western Reserve University) were linearized with XbaI (New England Biolabs) and used as the backbone for the generation of recombinant viruses with the Env fragments. The EGFP- or DsRed2-tagged recombinant viruses were generated by cotransfecting equal molar amounts of the PCR-amplified entire env fragment and linearized NL4.3
EnvEGFP or NL4.3
EnvDsRed2 vector into 293T cells (at a density of 2.5 x 106 cells/per 10-cm culture dish) with FuGENE 6, according to the manufacturer's protocol (Roche, Indianapolis, IN). Culture supernatants were harvested at 60 h posttransfection, filtered through 0.45-µm-pore-size sterile syringe filters (Millipore), and stored at –80°C for titration and growth competition analyses.
Growth competition assays for evaluation of viral fitness. Growth competition experiments involve coinfection of a cell culture by the different HIV isolates. In our assays, cells were exposed to a mixture of two viruses or to each of the two virus individually; the number of cells infected by each virus in the dual infection after several rounds of infection was compared to the number of infected cells during monoinfection by each of the two viruses (7, 25, 29, 30). Single infection and competition experiments were performed in triplicate with EGFP- or DsRed2-tagged recombinant viruses using TZM-bl or U87-CD4-CCR5 cells grown in 24-well cell culture plates. NL4.3 EGFP- or DsRed2-tagged recombinant viruses were used as positive controls. Cells were infected with two competing viruses at an equal multiplicity of infection (MOI): 0.01 for TZM-bl and 0.005 for U87-CD4-CCR5 cells. Infections were carried out with 5 x 104 cells/well in 24-well cell culture plates at 37°C and 5% CO2 for 24 h. The cells were washed three times with phosphate-buffered saline and then cultured in complete DMEM until harvesting. For the infection of peripheral blood mononuclear cells (PBMC), the PBMC from HIV-seronegative blood donors were obtained by Ficoll-Hypaque density gradient centrifugation of heparin-treated venous blood. Prior to HIV-1 infection, the cells were stimulated with 5 µg of phytohemagglutinin (Gibco BRL) per ml for 3 days and maintained in RPMI 1640 medium supplemented with 10% FBS (HyClone) and 10 U/ml of interleukin-2 (Gibco-BRL). All mono- and dual-infection/competition experiments were performed at an MOI of 0.001 in PBMC in triplicate. Following a 6-h incubation at 37°C with 5% CO2, cells were washed three times with 1x phosphate-buffered saline and then resuspended in complete medium (106/ml) on 24-well plates. At 14 days postinfection, viruses were harvested and analyzed.
Quantitation of cells infected with EGFP- or DsRed2-tagged HIV-1 by flow cytometry. Infection was monitored daily for the presence of fluorescent cells using a Eclipse TE300 inverted upright wide-field fluorescence microscope (Nikon, Japan). Optimal signal of the cells infected with EGFP- or DsRed2-tagged HIV-1 from both single and dual infections was observed at 5 days postinfection. Cells were then harvested and analyzed by flow cytometry using a FACSCalibur instrument and Cell Quest Pro software (Becton Dickinson).
Evaluation of viral fitness. The fitness values were calculated based on the amounts of viruses produced during dual infections compared to amounts obtained from monoinfections. The amount of virus produced was determined by counting the number of cells that were infected by either the green- or red-tagged virus at 5 days postinfection using flow cytometry. In our HIV-1 competition experiments, the initial ratio of the competing viruses was 1:1. The fitness values were calculated with the formula shown in Fig. 1C. The amount of an individual HIV-1 isolate in a dual infection at the end of competition (f0) was divided by the amount of the same virus resulting from a monoinfection assay (i0), using the same initial inoculum as in the competition assay to derive a single-virus fitness value, W (W = f0/i0). The relative fitness value (W) for each virus was obtained from the average of the triplicate results in the competition assay. The ratio of the relative fitness value of each HIV-1 variant in the competition is a measurement of the fitness differences (Wd) between the infant and maternal viruses (Wd = Wi/Wm), where Wi and Wm correspond to the relative fitness of the infant and maternal viruses, respectively (30). Any variation in quantitation efficiency of flow cytometry was compensated by dividing the level of fluorescence of the specific virus from competition by the level of fluorescence from a single infection (2).
![]() View larger version (26K): [in a new window] |
FIG. 1. Construction of EGFP/DsRed2-tagged recombinant HIV-1 and fitness analysis. (A) Generation of HIV-1-EGFP/DsRed2-tagged recombinant viruses. PCR-amplified products of the entire env fragment were cotransfected with Xba1-linearized HIV-1 NL4.3 env EGFP/DsRed2 backbone vector into 293T cells. Viruses were harvested at 60 h after cotransfection. LTR, long terminal repeat. (B) Competition assay. Virus was added alone or in pairs to U87-CD4-CCR5 cells at an equal MOI of 0.005. Cells were harvested at day 5 postinfection and analyzed by fluorescence-activated cell sorter analysis. R, DsRed2-tagged virus; G, EGFP-tagged virus. (C) Relative fitness values calculation. Relative fitness values were calculated as shown. FL1 is the background intensity on the EGFP detector in a culture infected by a DsRed2-tagged virus (R), and FL2 is the background intensity on the DsRed2 detector in a culture infected by a EGFP-tagged virus (G). The number in the quadrant shows the percentage of green or red fluorescent cells in each single or dual infection. (D) EGFP and DsRed2 expression level in TZM-bl cells after single or dual infection with HIV-1 NL4.3 EGFP- or HIV-1 NL4.3 DsRed2-tagged recombinant viruses at an MOI of 0.01. The bars show the percentage of cells expressing EGFP or DsRed2 in each single or dual infection. (E) The relative fitness values of NL4.3 EGFP and DsRed2 viruses, respectively. (F) Analysis of dual infection/competition. HIV-1 NL4.3 DsRed2 competed against two randomly selected subtype C EGFP-tagged recombinant viruses in TZM-bl cells. The bars show the relative replicative fitness value of each virus. The scale of the y axis is 0.4, with higher relative fitness values above 1 and lower relative fitness values below 1.
|
Statistical analyses.
A Shapiro-Wilk test was used to analyze the pattern of distribution of fitness values. A relative fitness value (W) and standard deviation of relative fitness values were calculated for each MIP; the statistical significance between two different groups of MIPs was determined by the Student paired t test. P values of
0.05 were considered to be significant.
|
|
|---|
To further validate the assay, dual infections were carried out between NL4.3 and subtype C Env chimeric viruses from our patients. Based on published studies (4), we anticipated that subtype B NL4.3 would outcompete recombinant subtype C viruses. As expected, NL4.3 outcompeted a representative recombinant subtype C virus (Fig. 1F), irrespective of whether DsRed2 or EGFP was used to identify the subtype C virus and the NL4.3 virus in the dual infection. Hence, the replicative fitness variation between the two competing viruses is attributed to differences in Env and not due to the viral backbone or the fluorescent tags.
The infant recombinant viruses are more fit than the maternal recombinant viruses from chronically infected MIPs. We had previously characterized the env genes from the five infants whose mothers were chronically infected (41). The phylogenetic analyses of Env V1-V5 sequences showed that the baseline infant viruses were more homogeneous than the mothers' in five MIPs where mothers were infected with HIV-1 chronically; a representative example of them is shown in Fig. 2A. This indicates either that selective transmission of a minor viral population occurred during perinatal transmission from each of these chronically infected mothers or that multiple HIV-1 variants may have entered the recipient but only minor variants were selectively amplified. To determine whether the replicative fitness of transmitted viruses in the infants was different from those in the maternal donor population, dual-infection competitions were performed between viruses carrying different maternal and infant viral env genes from the five MIPs that were previously analyzed (41). The env clones were selected in each MIP based on the following criteria: (i) the length of the Env V1-V5 fragment, (ii) the branch length of each Env in the phylogenetic tree, and (iii) the number of putative N-linked glycosylation sites. Four to seven env clones were selected from both the mother and the infant to generate recombinant viruses. To eliminate the possibility that the selected clones for the competition assay could be outliers, we then calculated the divergence for each selected clone of the MIP as the genetic distance between any sequence and the MRCA of the total previously analyzed archived virus sequences (41). The results showed that divergence from each selected env is within the range of the characterized population, and no outlier of divergence was used in our competition assays. As expected, the analyses of the representative MIP 2873 showed that divergence in pairwise comparison of the individual sequence and MRCA is somewhat higher in the env of the maternal viruses than the env of infant viruses, with the divergence distribution in the infant being more homogeneous (Fig. 3A and B). The divergence within each individual ranged from 0.001 to 0.043 (median, 0.007) and 0.001 to 0.008 (median, 0.002) in mother and infant, respectively. Similar results were obtained for the other four chronically infected MIPs (data not shown).
![]() View larger version (24K): [in a new window] |
FIG. 2. Phylogenetic analysis of HIV-1 Env V1-V5 sequences obtained from the baseline time point of two representative MIPs. (A) MIP 2873 is a representative of a chronically infected MIP described previously (41). (B) MIP 2660 is a representative of an acutely infected MIP described previously (14). Samples from infants are shown in filled symbols, and samples from mothers are shown in open symbols.
|
![]() View larger version (21K): [in a new window] |
FIG. 3. Divergence of the selected clones from the MRCA env sequences from a representative chronically infected MIP (2873) and a representative acutely infected MIP (2660). Pairwise comparisons between each individual maternal (A) and infant (B) viral Env from MIP 2873 and MRCA are arbitrarily distributed along the x axis. Pairwise comparisons between each individual maternal (C) and infant (D) viruses from MIP 2660 and MRCA are arbitrarily distributed along the x axis. Samples selected for this study are indicated by the arrows.
|
![]() View larger version (34K): [in a new window] |
FIG. 4. The competition assays of mother and infant viruses from representative chronically infected MIP 1084 with different fluorescence tags in U87-CD4-CCR5 cells and in PBMC. (A) A representative of pairwise competition of MIP 1084 at the baseline time point in U87-CD4-CCR5 cells at an MOI of 0.005 (mother, EGFP-tagged viruses; infant, DsRed2-tagged viruses). (B) The relative fitness values of recombinant viruses obtained from chronically infected MIP 1084 in U87 cells. (C) A representative of pairwise competition of MIP 1084 viruses using reciprocal fluorescence tags at a baseline time point in U87-CD4-CCR5 cells at an MOI of 0.005 (mother, DsRed2-tagged viruses; infant, EGFP-tagged viruses). (D) The relative fitness values of recombinant viruses obtained from chronically infected MIP 1084 in reciprocal fluorescence tags in U87 cells. (E) A representative of pairwise competition of MIP 1084 at the baseline time point in PBMC at an MOI of 0.001. (F) The relative fitness values of recombinant viruses obtained from chronically infected MIP 1084 in PBMC.
|
|
View this table: [in a new window] |
TABLE 1. Relative fitness value from pairwise competition of viruses from MIP 1084 in U87-CD4-CCR5 cellsa
|
![]() View larger version (34K): [in a new window] |
FIG. 5. The competition assays of mother and infant viruses from chronically and acutely infected MIPs. (A to D) The relative fitness values of recombinant viruses obtained from chronically infected MIPs 1449, 2669, 2617, and 2873 at the baseline time point in U87-CD4-CCR5 cells at an MOI of 0.005. (E and F) The relative fitness values of recombinant viruses obtained from acutely infected MIPs 834 and 2660. The gray bars represent infant viruses; the white bars represent maternal viruses from each pair. All competition experiments were performed in triplicate, and the error bars indicate standard deviation (SD) from triplicate results.
|
|
View this table: [in a new window] |
TABLE 2. Relative fitness value (W) from pairwise competition of viruses from MIP1084 in PBMC
|
|
View this table: [in a new window] |
TABLE 3. Fitness value differences from cross-competitions between nonidentical MIPs
|
|
View this table: [in a new window] |
TABLE 4. Relative fitness value from pairwise competition of viruses from acutely infected MIP 834 in U87-CD4-CCR5 cellsa
|
|
View this table: [in a new window] |
TABLE 5. Relative fitness values from pairwise competition of viruses from acutely infected MIP 834 in PBMC
|
|
|
|---|
There are a number of possible explanations to account for our observation that a minor viral population within the chronically infected mothers is transmitted. One is that only a minor population of the transmitted virus is infectious or replication competent in the new host (23, 34, 36, 40). A second is that the initial target cells restrict the replication of most transmitted viral genotypes. It has been postulated that macrophages, present in the mucosa and placental tissues, may be the first target cells that HIV-1 encounters and may select for a viral population that can preferentially infect these cells (6). The selective transmission could also be an outcome of immune selection by maternal antibodies. These antibodies could include neutralizing antibodies, which may play a role in limiting the transmission of neutralization-sensitive variants. Other studies using a macaque perinatal transmission model found that the infant viruses represent minor variants in their mothers and are more neutralization resistant (15, 16). Therefore, it is difficult to determine whether the transmission of more fit viruses to the infants is due to selective transmission or selective amplification in the recipient. In the five MIPs where mothers were chronically infected with HIV-1, most of the perinatally transmitted infants' specimens were obtained before 2 months of age except 1084i, which was obtained at 6 months. It is unlikely that the infants' immune systems mediate the selection since they are not yet fully developed. However, the maternal passive antibody that has neutralizing activity might play a role in selective amplification, in which minor variants were selectively amplified even though multiple HIV-1 variants might be perinatally transmitted, but not all studies are in agreement on the role of neutralizing antibodies in HIV-1 perinatal transmission. Maternal antibodies are known to cross the placenta beginning at 18 weeks of gestation to peak at delivery; antibodies persist in the infant for up to 18 month of age and may thus act to prevent HIV-1 infection in the infant both in utero and postpartum (9). In addition, during intrapartum exposure, major variants would be neutralized by passively transferred autologous neutralizing antibodies. However, minor variants which are resistant would be transmitted in the absence of broadly neutralizing antibodies, as suggested by Barin et al. (5). This possibility supports our data that only a subset of viruses with higher fitness, more adapted for transmission, was selected during perinatal transmission from the chronically infected mothers. This higher fitness may enable the transmitted virus to establish initial sites of replication (a beachhead) or to produce more progeny rapidly to adapt to growth in vivo and withstand the selection pressures imposed by perinatal transmission. Whether this subset of the viruses that we analyzed here is more resistant to neutralization needs to be determined. In contrast, in acutely infected mothers whose viruses had recently been selected during transmission, the viruses required no further selection during perinatal transmission, and viruses from both the mothers and infants had equal fitness, as we have observed. However, for the infants born to the chronically infected mothers analyzed, we do not know whether they were infected in utero, intrapartum, or postpartum via breast milk; further studies will be needed to determine whether selective transmission from chronically infected mothers is dependent on the route of transmission.
Although the growth competition assay used in our study uses a well-established methodology (38), recombination between the two competing viruses remained a concern. To address this concern, viral stocks were serially diluted to the minimal MOI to reduce the possibility of recombination between the two competing viruses. If recombination had been a problem, we would not have observed the consistently higher fitness of infant viruses. Another constraint is the small number of clones that were analyzed from each patient. This is due to the limited number of archived clones analyzed previously that were available for this study (41), and the clones were derived from PBMC rather than from plasma. Unfortunately, patient specimens such as plasma and PBMC DNA are no longer available to generate additional clones for further analyses, but quantitative analysis of Env V1-V5 divergence demonstrated that our available clones were representative of the virus population in our study. An additional constraint is that the clones were generated previously from the pooling of several bulk PCRs rather than from the single-genome PCR that has been used recently (32), and there is a possibility that the clones were generated from template resampling. However, our previous studies showed that the number of unique sequences is large and is similar at each time point (14, 41), suggesting that pooling individual PCR products is adequate to prevent virus template resampling in our study. If resampling were a problem, we would not have observed differences between the chronic and acute MIPs.
Selection of a minor viral genotype during perinatal transmission has been reported previously (3, 40); however, no report has correlated the restricted transmission of viral env genotypes to their biological properties. Our competition studies, which employed maternal and infant recombinant viruses that are identical except for the env V1-V5 region, suggest that this region of the HIV-1 env conferred the differences in fitness between the mother and infant viruses. However, we could not exclude the possibility that other viral genes such as gag and pol may also play a role in viral fitness. We also could not exclude the possibility that the chimeric Env in the NL4.3 backbone may confer differences in fitness compared to the native nonchimeric structure. However, this effect should be similar for all recombinant viruses generated from both chronic and acute MIPs. The notion that differences were observed between the chronic and acute MIPs suggests that higher replicative fitness was determined by the Env V1-V5. Since Env is involved in the viral entry process, differences in the fitness profiles of mother and infant viruses indicate that a majority of the maternal viruses may be less efficient in entry, either in binding or fusion kinetics or both, and confer a fitness disadvantage compared to a minor population that was transmitted perinatally. At this point it is not clear whether superior fitness is due to more efficient viral entry by the transmitted viruses or whether postentry events may also have an effect on fitness.
Our study provides the first clear evidence of the higher fitness of viruses from infants conveyed by env during perinatal transmission. High fitness of the virus upon transmission to a new host, in combination with a bottleneck during perinatal transmission, suggests that during the course of disease progression in the chronically infected mothers, the majority of the maternal viruses may have evolved or been selected for growth and persistence in the host but that only a minor population has retained its fitness for perinatal transmission. It is possible that this selection occurs in the female reproductive tract or breast. Whether such a selection occurs during sexual or blood-borne transmission needs to be determined. This finding may provide important information for the development of a vaccine to prevent perinatal transmission.
envEGFP and DsRed2 vectors, Lee Ratner (Washington University) for U87-CD4-CCR5 cells and helpful discussions, Charles A Kuszynski (Nebraska Medical Center) for assistance with flow cytometry, and Shiu-Lok Hu for reviewing the manuscript. 293T and TZM-bl cells were obtained from the NIH AIDS Research and Reference Reagent Program. This study was supported by PHS grants HD39620, CA75903, and T32 AI060547; Fogarty International grant TW001429; and NCRR COBRE grant RR15635 to C.W. X.K. and T.M. are Fogarty Fellows.
Published ahead of print on 10 September 2008. ![]()
Supplemental material for this article may be found at http://jvi.asm.org/. ![]()
Present address: School of Medicine, Nankai University, Tianjin, China, 300072. ![]()
Present address: University of Oklahoma Health Sciences Center, Department of Microbiology and Immunology, Oklahoma City, OK 73104. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»